预约演示
更新于：2025-06-01
Mitiglinide Calcium Hydrate
米格列奈钙
更新于：2025-06-01
概要
基本信息
药物类型 小分子化药 |
别名 Glinsuna、Mitiglinide、Mitiglinide calcium + [10] |
作用方式 阻滞剂 |
作用机制 KATP通道阻滞剂 |
治疗领域 |
在研适应症 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批日期 日本 (2004-01-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C38H54CaN2O8 |
InChIKeyGJJVODCYSACLPP-UZYHXJQGSA-N |
CAS号207844-01-7 |
关联
41
项与 米格列奈钙 相关的临床试验CTR20234251
米格列奈钙片随机、开放、交叉设计在中国健康受试者中的生物等效性正式试验
CTR20213240
米格列奈钙片(10mg)在健康受试者中的生物等效性试验
CTR20220245
米格列奈钙片在健康人体中的随机、开放、交叉设计、四周期高脂餐后口服生物等效性试验
100 项与 米格列奈钙 相关的临床结果
登录后查看更多信息
100 项与 米格列奈钙 相关的转化医学
登录后查看更多信息
100 项与 米格列奈钙 相关的专利（医药）
登录后查看更多信息
297
项与 米格列奈钙 相关的文献（医药）2025-04-01MOLECULAR PHARMACOLOGY
Structural similarity-based search for glinides exhibiting cis- and trans-inhibitory activity toward uric acid transporter 1
Article
作者: Sayama, Misa ; Anzai, Naohiko ; Miyauchi, Seiji ; Ishii, Itsuko ; Reien, Yoshie ; Suzuki, Takaaki
Various types of drugs can affect serum urate levels as side effects. Although these drugs are used to treat different diseases, they might share a structural component that acts on a common target to affect urate levels. Human urate transporter 1 (URAT1) plays an essential role in urate reabsorption at the renal proximal tubule and thus might be a common target for drugs that can affect serum urate levels. Our aim was to elucidate the structural requirements for a compound to show activity toward URAT1 and to identify clinically used drugs that can affect URAT1 activity. Our search was based on structural similarities in the compounds. [14C]Urate uptake by URAT1-expressing human embryonic kidney 293 (HEK-hURAT1) cells in the presence of an analog of a small molecule with known URAT1 activity suggested that structural moieties of salicylic acid can increase URAT1 cis-inhibitory activity. Therefore, we searched a database for drugs with substructures similar to salicylic acid. We were able to predict some types of loop diuretics, statins, and angiotensin receptor blockers as drug candidates that might affect URAT1. In addition, we found that glinides inhibit urate uptake by HEK-hURAT1 cells. Three glinides (nateglinide, mitiglinide, and repaglinide) all inhibited urate uptake by HEK-hURAT1 cells concentration-dependently (IC50: nateglinide, 39 μM; mitiglinide, 63 μM; repaglinide, 3.9 μM). Furthermore, glinides also showed trans-inhibition activity in URAT1-expressing Xenopus oocytes pretreated with the glinides. These findings suggest that glinides sharing a salicylic acid-like substructure might affect serum urate level by acting on URAT1. SIGNIFICANCE STATEMENT: Some types of loop diuretics, statins, angiotensin receptor blockers, and glinides were predicted to affect URAT1, based on their chemical structural similarity to salicylic acid, the structure of which allows it to interact with URAT1. Glinides in particular showed cis- and trans-inhibitory activity toward URAT1.
2025-01-01JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
Non-targeted screening of illegal added hypoglycemic drugs and their derivatives in functional foods using characteristic fragment ions scanning based on liquid chromatography-high-resolution mass spectrometry
Article
作者: Liu, Yajie ; Feng, Feng ; Zhang, Feng ; Du, Rongzhu ; Wang, Xiujuan ; Feng, Xuesong
Functional foods that are illegally adulterated with chemical hypoglycemic drugs or their derivatives pose serious risks to human health. However, the detection of these compounds is a challenge due to the unknown nature of their structures, particularly as many of these compounds are newly synthesized and lack standardized references. In this study, we developed a non-targeted screening strategy for detecting illegally added hypoglycemic drugs and their derivatives in oral solution and hard capsule functional foods. This strategy utilizes a self-established characteristic fragment ions mass spectrum database based on ultrahigh-performance liquid chromatography-quadrupole/orbitrap high-resolution mass spectrometry. Nine characteristic fragment ions were identified by analyzing the mass spectrometric fragmentation patterns of hypoglycemic drugs. Meanwhile, the precursor and fragment ions of 38 known hypoglycemic drugs were collected and incorporated into the mass database. The detection limits of hypoglycemic drugs in oral solution and hard capsule samples were 0.01-10 μg/L and 0.01-50 μg/kg, respectively. Applying the non-targeted method to 20 batches of suspicious samples, we found that 3 batches of samples contained illegal added drugs. Furthermore, we identified a previously unrecorded hypoglycemic drug not present in the mass database. These results indicate that the developed strategy is a powerful tool for the rapid and highly sensitive identification of both known and unknown hypoglycemic drugs, as well as their derivatives in functional foods.
2024-04-01Journal of diabetes investigation
Comparative effects of fixed‐dose mitiglinide/voglibose combination and glimepiride on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial
Article
作者: Saito, Momo ; Tanaka, Yoshiya ; Tanaka, Kenichi ; Sonoda, Satomi ; Tomoyose, Yukiko ; Uemura, Fumi ; Hori, Yuri ; Tokutsu, Akemi ; Okada, Yosuke ; Hashimoto, Ryoma ; Kurozumi, Akira ; Umezu, Saeko ; Tateyama, Rina
ABSTRACT:
Introduction:
The aim of this study was to compare the effects of mitiglinide/voglibose with those of glimepiride on glycemic variability and vascular endothelial function in patients with type 2 diabetes.
Materials and Methods:
It was a multicenter, open‐label, randomized, crossover study. Hospitalized patients received either mitiglinide/voglibose (three times daily administration of 10 mg mitiglinide and 0.2 mg voglibose) or glimepiride (once‐daily 2 mg) in random order, each for 5 days. The reactive hyperemia index (RHI) and the mean amplitude of glycemic excursions (MAGE) were measured as co‐primary endpoints using reactive hyperemia peripheral arterial tonometry and continuous glucose monitoring.
Results:
The analysis included 30 patients (15 in each group). The RHI was 1.670 ± 0.369 during treatment with mitiglinide/voglibose and 1.716 ± 0.492 during treatment with glimepiride, with no significant difference between the two. MAGE was significantly lower in the mitiglinide/voglibose group (47.6 ± 18.5 mg/dL) than in the glimepiride group (100.6 ± 32.2 mg/dL). Although the mean blood glucose levels over the entire 24 h period were comparable between the two groups, the use of mitiglinide/voglibose was associated with a lower standard deviation of mean glucose, coefficient of variation, and mean postprandial glucose excursion compared with glimepiride. The time below range (<70 mg/dL) and the time above range (>180, >200, and 250 mg/dL) were lower in the mitiglinide/voglibose group, while the time in range (70–180 mg/dL) was higher.
Conclusions:
In our short‐duration randomized crossover study, although not impacting vascular endothelial function, mitiglinide/voglibose demonstrated potential benefits in reducing glycemic variability, postprandial hyperglycemia, and hypoglycemia in patients with type 2 diabetes.
100 项与 米格列奈钙 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 日本 | 2004-01-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 内分泌系统疾病 | 临床1期 | 中国 | 2012-11-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 178 | Insulin+KAD-1229 (Placebo/KAD-1229) | 衊繭鹹齋壓鹹築選選夢(築窪憲範鹹餘願繭夢醖) = 窪蓋鬱壓觸積艱艱膚醖 襯壓選積觸鑰選繭夢壓 (鏇艱餘鹹獵醖顧鹽鹹顧, 1.04) | - | 2019-09-06 | ||
Insulin+KAD-1229 (KAD-1229/KAD-1229) | 衊繭鹹齋壓鹹築選選夢(築窪憲範鹹餘願繭夢醖) = 淵遞獵簾餘構製築鹹製 襯壓選積觸鑰選繭夢壓 (鏇艱餘鹹獵醖顧鹽鹹顧, 0.87) | ||||||
临床3期 | 156 | insulin glargine+mitiglinide | 餘構窪願衊衊壓襯願膚(壓鏇襯餘餘簾廠醖醖齋) = 蓋構鬱顧鏇餘遞夢鏇範 願艱積遞網鬱淵簾夢範 (願鑰鬱遞構壓衊構簾醖 ) | 非劣 | 2015-01-01 | ||
insulin glargine+voglibose | 餘構窪願衊衊壓襯願膚(壓鏇襯餘餘簾廠醖醖齋) = 鏇夢衊壓衊糧膚簾製憲 願艱積遞網鬱淵簾夢範 (願鑰鬱遞構壓衊構簾醖 ) | ||||||
临床1期 | 26 | 選淵顧顧鏇鹽鏇艱遞膚(齋觸繭構選糧遞壓憲糧) = 繭鏇餘鬱鏇夢顧製壓鬱 選鬱顧蓋齋鏇範鏇繭艱 (鑰鹽遞餘網鹹衊夢選蓋 ) | 积极 | 2013-11-01 | |||
Sitagliptin alone | 選淵顧顧鏇鹽鏇艱遞膚(齋觸繭構選糧遞壓憲糧) = 齋淵鏇積醖鑰築製鏇築 選鬱顧蓋齋鏇範鏇繭艱 (鑰鹽遞餘網鹹衊夢選蓋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用